Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AdCLD-CoV19-1 OMI / Cellid
NCT05993325: Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers	Active, not recruiting	3	4000	RoW	AdCLD-CoV19-1 OMI, Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)	Cellid Co., Ltd.	COVID-19, Vaccines	03/25	11/25
NCT05576623: Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine	Completed	1/2	320	RoW	AdCLD-CoV19-1 OMI (Part A), AdCLD-CoV19-1 OMI (Part B), Placebo (Part B)	Cellid Co., Ltd.	COVID-19, Vaccines	03/23	02/24